Civilization Ventures Announces $35M Second Fund

SAN FRANCISCO--(BUSINESS WIRE)---- $NVTA #VC--Civilization Ventures is announcing the close of its second fund following the successful investment of Fund I in 2017, where the firm had major portfolio exits with the public listing of gene therapy leader Rocket Pharma (NASDAQ: RCKT) and the acquisition of Singular Bio by Invitae, Inc. (NYSE: NVTA), a publicly traded company at the forefront of advanced medical genetics. Civilization Ventures will use its new capital to power the most innovative life science c

Click to view original post